Leveraging Black pharmacists to promote equity in COVID-19 vaccine uptake within Black communities: A framework for researchers and clinicians.

Black Americans are disproportionately represented among coronavirus disease 2019 (COVID-19)-related morbidities and mortalities. While the COVID-19 vaccines are positioned to change this disparity, vaccine hesitancy, attributed to decades of systemic racism and mistreatment by the United States health care system, heavily exists among this racially and ethnically minoritized group. In addition, social determinants of health within Black communities including the lack of health care access and inequitable COVID-19 vaccine allocation, further impacts vaccine uptake. Black pharmacists have worked to address the pandemic's deleterious effects that have been recognized within Black communities, as they are intimately aware of the structural and systematic limitations that contribute to lower vaccination rates in comparison to other racial and ethnic groups. Black pharmacists have been integral to promoting equity in COVID-19 uptake within Black communities by disseminating factual, trustworthy information in collaboration with community leaders, advocating for the equitable access to the immunizations into vulnerable areas, and creating, low-barrier, options to distribute the vaccines. Herein, we thoroughly explain these points and offer a framework that describes the role of Black pharmacists in narrowing vaccine equity gaps.

Evaluation of 3 Months of Once-Weekly Rifapentine and Isoniazid for Latent Tuberculosis Infection.

Background: Centers for Disease Control and Prevention recommends 3 months of once-weekly rifapentine/isoniazid (3HP) for latent tuberculosis infection (LTBI) treatment given by directly observed therapy (DOT) or self-administered therapy (SAT) in patients ≥2 years old. 3HP has been associated with increased incidence of hepatic, gastrointestinal, flu-like, and cutaneous adverse drug reactions (ADRs) compared with isoniazid monotherapy. Objective: This study evaluated 3HP completion rates and tolerability for LTBI treatment in a real-world setting. Methods: A single-center retrospective cohort with a nested case-control study, comparing patients experiencing ADRs with those who did not, evaluated patients ≥18 years old receiving 3HP by DOT or SAT for LTBI at Cleveland Clinic from October 2011 through July 2018. Information on baseline characteristics, 3HP administrations, and ADRs were collected. Results: Of 199 patients screened, 144 were included (111 DOT, 33 SAT). 3HP completion rates were high at 82.6% and similar between DOT and SAT groups. During treatment, 92/144 (63.9%) patients experienced any ADR. The most common ADR included flu-like symptoms (38.2%) and gastrointestinal (31.9%) and hepatic (2.1%) reactions. Despite high rate of overall ADRs, rates of significant ADRs (grade 2 or higher) were 4.2%. Overall, 9% of patients discontinued 3HP because of ADRs. After adjusting for other factors associated with ADRs at baseline, SAT was not associated with increased incidence of ADRs, but female sex was a significant predictor (odds ratio = 2.61 [95% CI, 1.23 to 5.56]). Conclusion and Relevance: This study observed high 3HP treatment completion rates, low incidence of significant ADRs, and low discontinuation rates resulting from ADRs.